Research Papers:

Calcitriol and non-calcemic vitamin D analogue, 22-oxacalcitriol, attenuate developmental and pathological choroidal vasculature angiogenesis ex vivo and in vivo

Stephanie L. Merrigan, Bomina Park, Zaheer Ali, Lasse D. Jensen, Timothy W. Corson and Breandán N. Kennedy

PDF  |  Full Text  |  Supplementary Files  |  How to cite  |  Press Release

Oncotarget. 2020; 11:493-509. https://doi.org/10.18632/oncotarget.27380

Metrics: PDF 1345 views  |   Full Text 2145 views  |   ?  


Stephanie L. Merrigan1, Bomina Park2,3, Zaheer Ali4, Lasse D. Jensen4, Timothy W. Corson2,3 and Breandán N. Kennedy1

1 UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin D04 V1W8, Ireland

2 Eugene and Marilyn Glick Eye Institute, Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, Indiana, USA

3 Department of Pharmacology and Toxicology, Indiana University School of Medicine, Indianapolis,Indiana, USA

4 Division of Cardiovascular Medicine, Department of Medical and Health Sciences, Linköping University, Linköping, Sweden

Correspondence to:

Breandán N. Kennedy,email: [email protected]

Keywords: developmental angiogenesis; pathological angiogenesis; ocular angiogenesis; calcitriol; 22-oxacalcitriol

Received: July 22, 2019     Accepted: October 19, 2019     Published: February 04, 2020


Aberrant ocular angiogenesis can underpin vision loss in leading causes of blindness, including neovascular age-related macular degeneration and proliferative diabetic retinopathy. Current pharmacological interventions require repeated invasive administrations, may lack efficacy and are associated with poor patient compliance and tachyphylaxis. Vitamin D has de novo anti-angiogenic properties. Here, our aim was to validate the ocular anti-angiogenic activity of biologically active vitamin D, calcitriol, and selected vitamin D analogue, 22-oxacalcitriol. Calcitriol induced a significant reduction in ex vivo mouse choroidal fragment sprouting. Viability studies in a human RPE cell line suggested non-calcemic vitamin D analogues including 22-oxacalcitriol have less off-target anti-proliferative activity compared to calcitriol and other analogues. Thereafter, the anti-angiogenic activity of 22-oxacalcitriol was demonstrated in an ex vivo mouse choroidal fragment sprouting assay. In zebrafish larvae, 22-oxacalcitriol was found to be anti-angiogenic, inducing a dose-dependent reduction in choriocapillaris development. Subcutaneously administered calcitriol failed to attenuate mouse retinal vasculature development. However, calcitriol and 22-oxacalcitriol administered intraperitoneally, significantly attenuated lesion volume in the laser-induced choroidal neovascularisation mouse model. In summary, calcitriol and 22-oxacalcitriol attenuate ex vivo and in vivo choroidal vasculature angiogenesis. Therefore, vitamin D may have potential as an interventional treatment for ophthalmic neovascular indications.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 27380